Medical condition
Pain
Pain is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- duloxetine (APO-DULOXETINE) Nervous system (N06)
- eptifibatide (EPTIFIBATIDE ACCORD) Blood and blood forming organs (B01)
- bupivacaine (EXPAREL LIPOSOMAL) Nervous system (N01)
- pregabalin (APO-PREGABALIN) Nervous system (N02)
- pentosan polysulfate sodium (ELMIRON) Genito-urinary system and sex hormones (G04)
- nepafenac (NEVANAC) Sensory organs (S01)
- capsaicin (QUTENZA) Nervous system (N01)
- fentanyl (ABSTRAL) Nervous system (N02)
- propranolol (APO-PROPRANOLOL) Cardiovascular system (C07)
- phenylephrine (OMIDRIA) Sensory organs (S01)
- samarium [153sm] lexidronam pentasodium (QUADRAMET) Various (V10)
- sufentanil (DZUVEO) Nervous system (N01)
Latest Pain news
Lilly buys 4E in non-opioid pain push: what investors should watch
Eli Lilly is buying 4E Therapeutics, adding another non-opioid pain pipeline to its portfolio after the SiteOne transaction. The move comes as Journavx (suzetrigine) advances in the market and in multiple clinical trials.
FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
The FDA approved Vertex Pharmaceuticals’ Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults. The decision creates a new non-opioid catalyst to track for BD teams, investors, and analysts.
FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx
The FDA approved Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults, including postoperative pain. The decision gives Vertex the first non-opioid analgesic in this setting and creates a new catalyst set for BD teams, investors, and analysts.
Vertex launches Journavx after FDA approval for acute pain
Vertex’s Journavx (suzetrigine) became the first FDA-approved non-opioid analgesic for moderate to severe acute pain on January 30, 2025. This plan frames the catalyst, label, and upcoming clinical milestones for BD teams, investors, and analysts.
Contineum Therapeutics PIPE-791 Shows Positive Phase 1b Results for Chronic Osteoarthritis Pain
Contineum Therapeutics reports positive Phase 1b trial data for PIPE-791, a non-opioid LPA1 receptor antagonist for chronic osteoarthritis pain treatment.
BRC Therapeutics Receives FDA Clearance for BRC-002 Phase I Trial in Complex Regional Pain Syndrome
BRC Therapeutics gets FDA IND clearance for BRC-002, a first-in-class treatment for Complex Regional Pain Syndrome, advancing to Phase I safety trials.
Drug Testing for Substance Use and Pain Management
This medical policy outlines guidelines for urine drug testing in pain management and substance use treatment.
FDA Approves PainBlock Patch: Novel Delivery System for Chronic Pain
The FDA has approved the PainBlock Patch, a groundbreaking delivery system designed to provide effective relief for chronic pain sufferers.